SAB Biotherapeutics, Inc. Stock Price

NasdaqCM:SABS Community·US$274.1m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Create a narrative

SABS Share Price Performance

US$3.90

2.12 (119.10%)

US$3.90

2.12 (119.10%)

US$3.90

Tue, 26 May 26

Share Pricen/a

SABS Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

1 Reward

View Full Analysis

SAB Biotherapeutics, Inc. Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: -0.13
: 0%
: 0%
: 0%

View Full Analysis

About SABS

Founded: 2014
Employees: 86
CEO: Samuel Reich
WebsiteView website: www.sab.bio

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.